BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Podesta A, Lopez P, Terg R, Villamil F, Flores D, Mastai R, Udaondo CB, Companc JP. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991;36:216-20. [PMID: 1988266 DOI: 10.1007/BF01300759] [Cited by in Crossref: 95] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Saadi M, Yu C, Othman MO. A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis. J Clin Transl Hepatol 2014;2:45-52. [PMID: 26357617 DOI: 10.14218/JCTH.2013.00021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2016;11:CD008320. [PMID: 27849111 DOI: 10.1002/14651858.CD008320.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
3 Webb GJ, Rahman SR, Levy C, Hirschfield GM. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther 2018;47:1213-9. [PMID: 29468705 DOI: 10.1111/apt.14579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31:283-307. [PMID: 19603170 DOI: 10.1007/s00281-009-0164-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
5 Schlichting J, Leuschner U. Drug therapy of primary biliary diseases: classical and modern strategies. J Cell Mol Med 2001;5:98-115. [PMID: 12067457 DOI: 10.1111/j.1582-4934.2001.tb00144.x] [Reference Citation Analysis]
6 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Khanna A, Jones DE. Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therap Adv Gastroenterol 2017;10:791-803. [PMID: 29051789 DOI: 10.1177/1756283X17728669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
9 Floreani A, Sun Y, Zou ZS, Li B, Cazzagon N, Bowlus CL, Gershwin ME. Proposed therapies in primary biliary cholangitis. Expert Rev Gastroenterol Hepatol 2016;10:371-82. [PMID: 26577047 DOI: 10.1586/17474124.2016.1121810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
10 Tack M. Problems with the MetaBLIND study: An examination of data on blinding patients in trials with patient-reported outcomes. J Health Psychol 2021;:13591053211059391. [PMID: 34875934 DOI: 10.1177/13591053211059391] [Reference Citation Analysis]
11 Siemens W, Xander C, Meerpohl JJ, Antes G, Becker G. Drug treatments for pruritus in adult palliative care. Dtsch Arztebl Int 2014;111:863-70. [PMID: 25585583 DOI: 10.3238/arztebl.2014.0863] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Tarikci N, Kocatürk E, Güngör Ş, Topal IO, Can PÜ, Singer R. Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities. ScientificWorldJournal 2015;2015:803752. [PMID: 26240837 DOI: 10.1155/2015/803752] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
13 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Douglass A, Wallace K, Koruth M, Barelle C, Porter AJ, Wright MC. Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatol Int 2008;2:405-15. [PMID: 19669316 DOI: 10.1007/s12072-008-9093-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
15 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
16 Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, Elferink RPO, Beuers U; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials 2017;18:230. [PMID: 28535810 DOI: 10.1186/s13063-017-1966-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
17 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
18 Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Child 1993;69:141-3. [PMID: 8024298 DOI: 10.1136/adc.69.1.141] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
19 Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436-439. [PMID: 11839728 DOI: 10.1136/gut.50.3.436] [Cited by in Crossref: 140] [Cited by in F6Publishing: 111] [Article Influence: 7.0] [Reference Citation Analysis]
20 Sutaria N, Adawi W, Goldberg R, Roh YS, Choi J, Kwatra SG. Itch: Pathogenesis and treatment. J Am Acad Dermatol 2022;86:17-34. [PMID: 34648873 DOI: 10.1016/j.jaad.2021.07.078] [Reference Citation Analysis]
21 Siddique A, Kowdley KV. Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis. 2012;16:199-229. [PMID: 22541695 DOI: 10.1016/j.cld.2012.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
22 Gossard AA. Care of the cholestatic patient. Clin Liver Dis 2013;17:331-44. [PMID: 23540506 DOI: 10.1016/j.cld.2012.11.005] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
24 Khandelwal M, Malet PF. Pruritus associated with cholestasis. A review of pathogenesis and management. Dig Dis Sci 1994;39:1-8. [PMID: 8281842 DOI: 10.1007/BF02090052] [Cited by in Crossref: 36] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]